Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754105 | 0.96 | MAPT (0.30) | — | |
| SCHEMBL8005765 | 0.78 | PTGS1 (0.35) | KDM4EALDH1A1 | |
| SCHEMBL21120702 | 0.78 | GABRA1 (0.32) | — | |
| SCHEMBL21743160 | 0.75 | NISCH (0.39) | KDM4E | |
| SCHEMBL7817311 | 0.73 | ALOX15 (0.33) | — | |
| SCHEMBL17229700 | 0.71 | KCNK3 (0.32) | ALDH1A1 | |
| SCHEMBL25873389 | 0.71 | TSHR (0.32) | — | |
| SCHEMBL17229720 | 0.70 | F12 (0.31) | ALDH1A1 | |
| SCHEMBL17229693 | 0.70 | KDR (0.36) | ALDH1A1 | |
| SCHEMBL17229772 | 0.70 | TSHR (0.32) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047905-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-10336727-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10040779-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170174656-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040779-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM5C | KDM4E 16/4885ALDH1A1 306/4885 |
| US-20170174656-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM5C | KDM4E 16/4885ALDH1A1 306/4885 |
| US-20230047905-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KDM4E 3761/4885ALDH1A1 4654/4885 |
| US-10336727-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM5C | KDM4E 16/4885ALDH1A1 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.